SLS - Sellas Life Sciences Group - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

SLS is currently covered by 2 analysts with an average price target of $5.31. This is a potential upside of $3.75 (240.38%) from yesterday's end of day stock price of $1.56.

Sellas Life Sciences Group's activity chart (see below) currently has 12 price targets and 10 ratings on display. The stock rating distribution of SLS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 16.67% with an average time for these price targets to be met of 69 days.

Highest price target for SLS is $6, Lowest price target is $6, average price target is $4.5.

Most recent stock forecast was given by AYDIN HUSEYNOV from LADENBURG on 15-May-2024. First documented stock forecast 08-Apr-2019.

Best performing analysts who are covering SLS - Sellas Life Sciences Group:

Jason Mccarthy Li Watsek Jim Molloy Aydin Huseynov

Currently out of the existing stock ratings of SLS, 3 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$6

$4.44 (284.62%)

$13

11 months 25 days ago
(15-May-2024)

0/3 (0%)

$4.53 (308.16%)

Buy

$3

$1.44 (92.31%)

$3

1 years 5 months 19 days ago
(21-Nov-2023)

0/5 (0%)

$1.99 (197.03%)

Buy

$4

$2.44 (156.41%)

$12

2 years 1 months 21 days ago
(19-Mar-2023)

2/3 (66.67%)

$2.72 (212.50%)

276

Buy

$8

$6.97 (676.70%)

$14

2 years 5 months 25 days ago
(15-Nov-2022)

0/3 (0%)

$5.76 (257.14%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is SLS (Sellas Life Sciences Group) average time for price targets to be met?

On average it took 69 days on average for the stock forecasts to be realized with a an average price target met ratio 16.67

Which analyst has the current highest performing score on SLS (Sellas Life Sciences Group) with a proven track record?

JASON MCCARTHY

Which analyst has the current lower performing score on SLS (Sellas Life Sciences Group) with a proven track record?

AYDIN HUSEYNOV

Which analyst has the most public recommendations on SLS (Sellas Life Sciences Group)?

Jason Mccarthy works at MAXIM GROUP and has 2 price targets and 2 ratings on SLS

Which analyst is the currently most bullish on SLS (Sellas Life Sciences Group)?

Jim Molloy with highest potential upside - $6.97

Which analyst is the currently most reserved on SLS (Sellas Life Sciences Group)?

Li Watsek with lowest potential downside - $1.44

Sellas Life Sciences Group in the News

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

– 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months – – Overall Response Rate (ORR) of 67% Achieved in Patients with AML-MRC (Target Patient Population of SLS009 in r/r AML) – Exceeding Targeted...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?